Literature DB >> 11762956

Infliximab treatment of severe ankylosing spondylitis: one-year followup.

J Brandt, H Haibel, J Sieper, J Reddig, J Braun.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11762956     DOI： 10.1002/1529-0131(200112)44:12<2936::aid-art483>3.0.co;2-m

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN： 0004-3591


× No keyword cloud information.
  18 in total

Review 1.  International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors:  J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2003-09       Impact factor: 19.103

2.  Possible predictors for relapse from etanercept discontinuation in ankylosing spondylitis patients in remission: a three years' following-up study.

Authors:  Minjing Zhao; Pingping Zhang; Linkai Fang; Zhongxing Luo; Jieruo Gu; Zhiming Lin
Journal:  Clin Rheumatol       Date:  2017-08-07       Impact factor: 2.980

3.  Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

Authors:  A Boonen; D van der Heijde; J L Severens; A Boendermaker; R Landewé; J Braun; J Brandt; J Sieper; Sj van der Linden
Journal:  Ann Rheum Dis       Date:  2005-07-13       Impact factor: 19.103

Review 4.  Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Authors:  J Braun; J Sieper; M Breban; E Collantes-Estevez; J Davis; R Inman; H Marzo-Ortega; H Mielants
Journal:  Ann Rheum Dis       Date:  2002-12       Impact factor: 19.103

5.  [Lessons learnt from 15 years of investigator-initiated trials on axial spondyloarthritis].

Authors:  J Sieper; J Braun
Journal:  Z Rheumatol       Date:  2015-03       Impact factor: 1.372

Review 6.  Expanding the armamentarium for the spondyloarthropathies.

Authors:  Paul M Peloso; Jürgen Braun
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

Review 7.  [Biologics in the early treatment of ankylosing spondylitis and related forms of spondyloarthritis].

Authors:  Hans-Eckhard Langer
Journal:  Wien Med Wochenschr       Date:  2008

8.  An international study on starting tumour necrosis factor-blocking agents in ankylosing spondylitis.

Authors:  T Pham; R Landewé; S van der Linden; M Dougados; J Sieper; J Braun; J Davis; M Rudwaleit; E Collantes; R Burgos-Vargas; J Edmonds; I Olivieri; I van der Horst-Bruinsma; H Mielants; M Stone; P Emery; D van der Heijde
Journal:  Ann Rheum Dis       Date:  2006-02-07       Impact factor: 19.103

9.  [Ankylosing spondylitis in Central and Eastern Europe. Cross-sectional study on treatment modalities, disease activity and quality of life].

Authors:  W Ebner; T Palotai; C Codreanu; P Géher; A Pahor; K Pavelka; J Smolen; J Szechiński; M Zlnay
Journal:  Z Rheumatol       Date:  2008-10       Impact factor: 1.372

10.  Infliximab in the treatment of ankylosing spondylitis.

Authors:  Rebecca Grainger; Andrew A Harrison
Journal:  Biologics       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.